Compare CVS Health Corp (CVS) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Lululemon Athletica Inc — how do they compare? CVS Health Corp trades at $94.78 (market cap $119.58B), while Lululemon Athletica Inc trades at $120.91 (market cap $14.26B). The key difference: CVS Health Corp is far larger — about 8.4× Lululemon Athletica Inc's market cap, and CVS Health Corp pays a 2.84% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| CVS | LULU | |
|---|---|---|
Market Cap | $119.58B | $14.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $215.88 |
52-Week Low | $65.51 | $105.43 |
Enterprise Value | $181.93B | $14.89B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.
CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.
Lululemon (LULU) trades at $121.4, down 5.01% amid broader market weakness in the premium apparel sector. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.69 beating expectations of $1.67. Valuation metrics appear attractive with P/E of 10.17 and P/S of 1.32, while profitability remains robust with 55.7% gross margins and 32.03% ROE. Technical indicators show a bullish moving average trend despite overbought RSI readings.
LULU presents a compelling investment case with undervalued metrics and strong international growth potential, particularly in China. However, risks include U.S. market softness and competitive pressures in the premium activewear space. The consensus price target of $129.29 suggests 6.5% upside potential from current levels, supported by 40.85% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
